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PURPOSE. Limited mechanistic understanding of diabetic retinopathy (DR) has hindered
therapeutic advances. Berberine, an isoquinolone alkaloid, has shown favorable effects on
glucose and lipid metabolism in animal and human studies, but effects on DR are unknown.
We previously demonstrated intraretinal extravasation and modification of LDL in human
diabetes, and toxicity of modified LDL to human retinal Mu¨ller cells. We now explore
pathogenic effects of modified LDL on Mu¨ller cells, and the efficacy of berberine in mitigating
this cytotoxicity.
METHODS. Confluent human Mu¨ller cells were exposed to in vitro–modified ‘highly oxidized,
glycated (HOG-) LDL versus native-LDL (N-LDL; 200 mg protein/L) for 6 or 24 hours, with/
without pretreatment with berberine (5 lM, 1 hour) and/or the adenosine monophosphate
(AMP)-activated protein kinase (AMPK) inhibitor, Compound C (5 lM, 1 hour). Using
techniques including Western blots, reactive oxygen species (ROS) detection assay, and
quantitative real-time PCR, the following outcomes were assessed: cell viability (CCK-8 assay),
autophagy (LC3, Beclin-1, ATG-5), apoptosis (cleaved caspase 3, cleaved poly-ADP ribose
polymerase), oxidative stress (ROS, nuclear factor erythroid 2-related factor 2, glutathione
peroxidase 1, NADPH oxidase 4), angiogenesis (VEGF, pigment epithelium-derived factor),
inflammation (inducible nitric oxide synthase, intercellular adhesion molecule 1, IL-6, IL-8,
TNF-a), and glial cell activation (glial fibrillary acidic protein).
RESULTS. Native-LDL had no effect on cultured human Mu¨ller cells, but HOG-LDL exhibited
marked toxicity, significantly decreasing viability and inducing autophagy, apoptosis,
oxidative stress, expression of angiogenic factors, inflammation, and glial cell activation.
Berberine attenuated all the effects of HOG-LDL (all P < 0.05), and its effects were mitigated
by AMPK inhibition (P < 0.05).
CONCLUSIONS. Berberine inhibits modified LDL-induced Mu¨ller cell injury by activating the
AMPK pathway, and merits further study as an agent for preventing and/or treating DR.
Keywords: angiogenesis, apoptosis, autophagy, berberine, diabetic retinopathy, GFAP,
inflammation, Mu¨ller cell, oxidative stress, oxidized LDL
Limited understanding of the pathogenic mechanisms under-lying diabetic retinopathy (DR) has hindered development of
new therapies. Both vascular and neuronal changes are believed
to play critical roles, but subclinical retinal injury is thought to
precede clinically detectable vascular injury.1 Mu¨ller cells are the
major glia of the retina; they form processes around retinal
vessels and provide support to retinal neurons, controlling blood
flow, modulating neuronal activity and glucose metabolism, and
maintaining the blood–retinal barriers (BRBs).2,3
Previously we have demonstrated that in people with diabetes,
LDL becomes extravasated through leaking BRBs, and subsequent-
ly modified by oxidation and glycation even in the ‘preclinical’
stages of DR.4–7 Therefore, we have postulated that in addition to
hyperglycemia, extravasation, and modification of plasma lipo-
proteins, with resultant cytotoxicity, are important drivers of DR.8
We found that among other adverse effects, modified LDL induces
death in several types of human retinal cells.5,6,9 Specifically,
Mu¨ller cell culture studies revealed that modified LDL causes
oxidative and endoplasmic reticulum (ER) stresses, and apoptotic
death, but the detailed underlying mechanisms of cellular injury
are not yet fully understood.9 Agents that could protect Mu¨ller
cells (and other retinal cells) from the toxic effects of modified
lipoproteins may hold therapeutic promise, and also shed light on
the mechanisms for DR.
Berberine (benzyltetrahydroxyquinoline; Fig. 1A) is natural
compound originally extracted from an herb, Huanglian (Copis
chinensis). It is a quaternary ammonium salt from the
protoberberine group of isoquinoline alkaloids, and has been
used in China for millennia as an antimicrobial agent.10,11 Long-
term clinical trials defining the safety of berberine are still not
available, but small, short-term studies show no evidence of
hepatic or renal toxicity.12,13 Recently, some favorable pharma-
cological actions of berberine have been demonstrated, includ-
ing anti-inflammatory, antioxidant, antidiabetic, and cholesterol-
lowering effects,14–18 as reviewed by Pang et al.18 Thus, in a
study of newly diagnosed type 2 diabetes mellitus, participants
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were randomly assigned to treatment with berberine or
metformin for three months19: berberine exhibited similar
glucose-lowering effects as metformin, and had greater benefi-
cial effects on plasma lipid profiles. Similar effects were shown
in another study in which berberine significantly lowered fasting
blood glucose, hemoglobin A1c, triglyceride, and insulin levels
in type 2 diabetic patients.20 These favorable effects have been
explored in vitro, and various signalling pathways have been
implicated.21–23 Importantly, many, perhaps most, effects of
berberine may be mediated through activation of the adenosine
monophosphate (AMP)-activated protein kinase (AMPK) path-
way. Little is known about possible effects of berberine in DR,
but some cell culture and animal studies suggest possible
benefit.24–28 In the current study, we aimed to test whether
berberine can protect cultured human retinal Mu¨ller cells
against cytotoxicity induced by oxidized-glycated LDL, and to
explore further the underlying pathogenic effects of the
lipoprotein, and the mechanisms of action of berberine.
MATERIALS AND METHODS
LDL Preparation, Modification, and
Characterization
Preparation of native-LDL (N-LDL) and ‘highly oxidized,
glycated’ LDL (HOG-LDL) was as described previously.5,29
Briefly, N-LDL (density ¼ 1.019–1.063) was isolated by
sequential ultracentrifugation of pooled plasma from 4 to 6
healthy fasted volunteers. Glycated LDL was prepared by
incubating LDL with freshly-prepared 50 mM glucose (72
hours, 378C) under antioxidant conditions (1 mM diethylene-
triaminepentaacetic acid [DTPA] with 270 lM EDTA, under
nitrogen). HOG-LDL was prepared by oxidizing the glycated
LDL in the presence of 10 lM copper chloride (24 hours,
378C), followed by repeated dialysis (48C, 24 hours). Protein
concentration of the LDL preparations was determined by the
Pierce BCA assay (Thermo Scientific, Rockford, IL, USA). Low-
density lipoprotein preparations were further characterized by
fluorescence (excitation: 360 nm; emission: 430 nm), agarose
gel electrophoresis (Paragon Lipo Gel; Beckman, Fullerton, CA,
USA) and absorbance at 234 nm. LDL preparations were stored
in the dark under nitrogen at 48C, in the presence of 270 lM
EDTA, and used within 6 weeks. Experiments were repeated
using different LDL preparations.
Human Retinal Mu¨ller Cell Culture
Moorfields/Institute of Ophthalmology-Mu¨ller 1 (MIO-M1)
cells, from a spontaneously immortalized human Mu¨ller cell
line, were provided by G. Astrid Limb (Institute of Ophthal-
mology, University College London, London, UK). Passages 22
to 25 were used for the current study. The cells were
FIGURE 1. Structure of berberine, and dose response on HOG-LDL–induced Mu¨ller cell death. (A) Berberine structure. (B) Mu¨ller cells were treated
with N- or HOG-LDL for 24 hours at various concentrations as indicated, or (C) pretreated with berberine (1.25–20 lM) for 1 hour followed by N- or
HOG-LDL (200 mg/L) exposure for 24 hours. Untreated cells served as control in this and the following figures (unless specifically indicated). Cell
viability was assessed by CCK-8 assay. Data are expressed as means 6 SD, n¼ 3. Statistical significance was determined by Student’s t-test, or 1-way
ANOVA, and P < 0.05 indicated significance in this and the following Figures. NS, not significant.
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maintained in Dulbecco’s modified Eagle’s medium/F12
(GIBCO, Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (Sigma-Aldrich, St. Louis, MO, USA) at 378C
under 5% CO2 and 95% air. Experiments were conducted on
cells that had reached 80% to 85% confluence. Berberine
chloride, 3-methyladenine (3-MA), Z-VAD-fmk, and N-acetylcys-
teine (NAC) were obtained from Sigma-Aldrich, and 4-
hydroxynonenal (4-HNE) was from Cayman Chemical (Ann
Arbor, MI, USA).
Cell Viability Assay
Human MIO-M1 Mu¨ller cells were seeded in 96-well plates
(10,000 cells/well) and cultured to 80% to 85% confluence,
then treated as described below. Cell viability was assessed
using the Cell Counting Kit-8 (CCK-8; Dojindo Molecular
Technologies, Rockville, MD, USA). In this indirect method, the
water-soluble tetrazolium salt, WST-8, is added to culture
medium, where as a result of intracellular dehydrogenase
activity, it is reduced to a highly colored, nontoxic formazan
dye. Absorbance at 450 nm was used to determine cell viability
per manufacturer’s instructions. All experiments were per-
formed in triplicate.
Western Blotting
Cells were homogenized with complete lysis buffer (Roche,
Indianapolis, IN, USA). Protein concentrations were measured
using Pierce BCA Assay Kit (Thermo Scientific). Thirty
micrograms of protein were loaded onto each lane of a gel.
Proteins were separated by 12% SDS-PAGE and transferred to
nitrocellulose membranes. Membranes were probed with
specific primary antibodies at dilutions of 1:1000 unless
indicated otherwise. Antibodies against b-actin (1:3000),
autophagy-related homologue 5 (ATG-5), Beclin-1, LC3, cleaved
poly-ADP ribose polymerase (PARP), cleaved caspase-3, glial
fibrillary acidic protein (GFAP), phospho-AMPK (p-AMPK) and
total AMPK (t-AMPK) were purchased from Cell Signalling
Technology (Danvers, MA, USA); antibodies against NADPH
oxidase 4 (Nox4), nuclear factor erythroid 2-related factor 2
(Nrf2), glutathione peroxidase 1 (Gpx-1), VEGF, pigment
epithelium-derived factor (PEDF), inducible nitric oxide
synthase (iNOS), and intercellular adhesion molecule 1
(ICAM-1) were purchased from Abcam (Cambridge, MA,
USA). b-actin was used as a loading control. All experiments
were repeated three times independently and quantified by
densitometry.
Measurement of Intracellular Reactive Oxygen
Species (ROS)
Intracellular ROS were measured by the DCFDA Cellular ROS
detection Assay Kit (Abcam), according to the manufacturer’s
instructions. Briefly, Mu¨ller cells were seeded in 96-well plates
at 13 104 cells per well. At 70% to 80% confluence, cells were
washed, then incubated with 20 lM DCFDA in phenol red-free
medium (378C, 45 minutes). After washing twice more, cells
were exposed to experimental conditions as described below.
Fluorescence signals were read at excitation 485 nm/emission
535 nm (VICTOR3 microplate reader; PerkinElmer, Waltham,
MA, USA). Data were presented as fold change versus control
after background subtraction.
Quantitative Real-Time PCR
RNA was extracted from Human MIO-M1 Mu¨ller cells (RNeasy
Mini Kit; Qiagen, Valencia, CA, USA). Complementary (c)DNA
was synthesized using Superscript III (Invitrogen Ltd., Paisley,
UK). Semiquantitative real-time PCR was performed using gene
specific Real Time ready Custom Single assays for IL-6, IL-8,
TNF-a, and b-actin (Roche). Relative quantitative values were
obtained using the DDCt method.
Statistical Analysis
Data are expressed as means 6 SD. Statistical significance was
determined by Student’s t-test, or 1-way ANOVA followed by post
hoc Bonferroni test as appropriate (Prism 4; Graphpad, La Jolla,
CA, USA). P values less than 0.05 were considered significant.
RESULTS
Berberine Attenuated HOG-LDL–Induced Mu¨ller
Cell Death
As expected, over 24 hours, HOG-LDL, but not N-LDL,
decreased Mu¨ller cell viability at concentrations greater than
or equal to 50 mg protein/L in a dose-dependent manner (Fig.
1B). To evaluate the effect of berberine on LDL-cell interac-
tions, we employed N-LDL and HOG-LDL at 200 mg/L, a
concentration we consider to be pathophysiologically relevant
in DR.8 Native-LDL did not affect cell viability, while HOG-LDL
reduced it by approximately 50% (Fig. 1B). Berberine (0–20
lM) either alone, or added as a pretreatment before exposure
to N-LDL, had no effect on Mu¨ller cell viability (Fig. 1C).
However, pretreatment with berberine for 1 hour significantly
improved viability following 24-hour exposure to HOG-LDL in
a dose-dependent manner (Fig. 1C). The lowest effective
concentration, 5 lM, was used in all the experiments described
below.
Berberine Attenuated HOG-LDL–Induced
Autophagic Cell Death
We previously showed that both autophagic cell death and
apoptosis contribute to HOG-LDL–induced retinal pericyte
loss,5 and that HOG-LDL can cause apoptosis in Mu¨ller cells.8
To determine if autophagy is also implicated in Mu¨ller cell
responses to HOG-LDL, we pretreated cells for 1 hour with 3
MA, a specific inhibitor of phosphoinositide 3-kinase, before
exposure to lipoproteins (200 mg/L in this and following
experiments) for 24 hours. 3 MA inhibits the initial phase of
the autophagic process, and it reduced HOG-LDL–induced
autophagy (Supplementary Fig. S1). As shown in Figure 2A,
loss of Mu¨ller cell viability was partially prevented by 3 MA
pretreatment, implicating autophagy in HOG-LDL–induced cell
death. We also genetically inhibited autophagy by knocking
down ATG-5 or Beclin-1, two key autophagy-related genes
(Supplementary Figs. S2A, S2B). Again, HOG-LDL–induced cell
death was attenuated (Fig. 2B). HOG-LDL–induced autophagy
was confirmed by Western blot, which showed significantly
increased protein levels of ATG-5, Beclin-1, and the ratio of
LC3II/LC3I. HOG-LDL–induced autophagy was attenuated by
berberine (Figs. 2C, 2D).
Berberine Attenuated HOG-LDL–Induced Apoptosis
As expected, we found, as before,8 that apoptosis was
implicated in HOG-LDL–induced Mu¨ller cell death over 24
hours, evidenced by the protective effect of ZAD-fmk, an
inhibitor of caspase-dependent apoptosis (Fig. 3A), and by
increased cleavage of PARP (cleaved PARP, molecular weight:
89 kD, Fig. 3B) and activation of caspase 3 (cleaved caspase,
molecular weight: 18 kD, Fig. 3C). Again, a protective effect of
berberine was observed (Figs. 3B, 3C).
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Berberine Attenuated HOG-LDL–Induced Oxidative
Stress, and Oxidative Stress may be Implicated in
Both Autophagy and Apoptosis
Previously, we have shown that oxidative stress is implicated
in HOG-LDL–induced apoptosis in retinal cells, including
Mu¨ller cells.5,6,9 We hypothesize that the protective role of
berberine against cell death, whether autophagic or apoptot-
ic, might operate through inhibition of oxidative stress. To
test this, cells were pretreated with NAC (100 lM, 1 hour)
before exposure to HOG-LDL for 24 hours, then markers for
autophagy and apoptosis were measured. NAC, a scavenger of
ROS, significantly mitigated HOG-LDL–induced LC3 conver-
sion and caspase activation, supporting a role for oxidative
stress in HOG-LDL–induced autophagy and apoptosis (Figs.
4A, 4B). We also measured intracellular levels of ROS and
proteins related to oxidative stress. We found that berberine
ameliorated excess ROS production by Mu¨ller cells (Fig. 4C).
Moreover, oxidative stress–induced expression of Nox4 and
decreased expression of Nrf2 and Gpx-1 were also mitigated
by berberine (Figs. 4D, 4F). All these data suggest that the
protective mechanism of berberine involves mitigation of
oxidative stress.
Berberine Attenuated HOG-LDL–Induced
Angiogenesis and Inflammation
Increased angiogenesis and inflammation are known features of
DR. Proangiogenic VEGF and antiangiogenic PEDF are two
major proteins balancing angiogenesis in the retina, and both are
perturbed in DR.30,31 Using Western blots, we confirmed that
over 24 hours, HOG-LDL increased VEGF and decreased PEDF
expression (Figs. 5A, 5B). This HOG-LDL–induced shift in
angiogenic balance (increased VEGF/PEDF ratio) was mitigated
by berberine (Fig. 5C). Berberine also reduced expression of
inflammatory cytokines: by Western blot, it attenuated the HOG-
LDL–induced increases in protein levels of iNOS and ICAM-1
(Fig. 5D), and by quantitative (q)PCR, it mitigated HOG-LDL–
induced expression for IL-6, IL-8, and TNF-a (Fig. 5E).
Berberine Blunted HOG-LDL–Induced GFAP
Upregulation
Glial fibrillary acidic protein is a structural protein which is
predominantly expressed in Mu¨ller cells, and is upregulated in
response to retinal injury or stress. Over 24 hours, HOG-LDL,
but not N-LDL, significantly increased GFAP expression, and
berberine inhibited the increase (Fig. 6).
FIGURE 2. Berberine attenuated HOG-LDL induced autophagic death in Mu¨ller cell. (A) Mu¨ller cells were pretreated with 3 MA (5 mM) for 1 hour,
or (B) transfected with Si-ATG-5 or Si-Beclin-1 for 36 hour then treated (in this and following experiments) with N- or HOG-LDL (200 mg/L) for 24
hour. Cell viability was expressed as percentage versus control (mean 6 SD, n¼ 3). (C, D) Mu¨ller cells were pretreated with berberine (5 lM) for 1
hour then exposed to N- or HOG-LDL for 24 hours. ATG-5, Beclin-1, LC3I, and LC3II were detected by Western blot and quantified by densitometry
(mean 6 SD; n¼ 3).
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AMPK Activation is Implicated in the Protective
Role of Berberine on Mu¨ller Cells
Adenosine monophosphate-activated protein kinase (AMPK) is
a sensor of cellular energy status. Previously, it has been
implicated in the favorable metabolic effects of berberine in
diabetes and cardiovascular disease.32,33 We found that in
Mu¨ller cells, berberine activates the AMPK pathway in a dose-
dependent (0–20 lM) and time-dependent (0–24 hours)
manner (Figs. 7A, 7B): its effect was maximal at 5 lM and
was observed within 1 hour. Similar activation by berberine
was observed in the presence of N- or HOG-LDL (cells treated
FIGURE 3. Berberine attenuated HOG-LDL–induced Mu¨ller cell apoptosis. (A) Mu¨ller cells were exposed to HOG-LDL for 24 hours with/without 1
hour pretreatment with Z-VAD-fmk (100 lM). Cell viability was expressed as percentage versus control (mean 6 SD, n¼3). (B, C) Mu¨ller cells were
exposed to N- or HOG-LDL for 24 hours with/without berberine (5 lM) pretreatment for 1 hours. Cleaved PARP and cleaved caspase-3 were
detected by Western blot and quantified by densitometry (mean 6 SD; n¼ 3).
FIGURE 4. Berberine decreased HOG-LDL–induced oxidative stress. Mu¨ller cells were pretreated with/without NAC (100 lM) or berberine (5 lM)
for 1 hour, then exposed to N- or HOG-LDL for 6, 12, or 24 hours: (A) autophagy marker, LC3, 24 hours; (B) apoptosis marker cleaved caspase-3, 24
hours; (C) cellular ROS levels, 6 hours, and (D–F) oxidative stress-related proteins, Nox4, Nrf2, and Gpx-1, 12 hours, were measured by DCFDA-
cellular ROS detection assay or by Western blot and quantified by densitometry (mean 6 SD; n¼ 3).
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with berberine for 1 hour, then lipoproteins added for 6
hours), although neither lipoprotein alone activated AMPK
(Fig. 7C). Compound C, a pharmacological inhibitor of AMPK,
was used to pretreat Mu¨ller cells, with or without berberine,
before exposure to LDL. The efficacy of Compound C as an
inhibitor of AMPK in Mu¨ller cells was confirmed by Western
blot (Fig. 8A). Compound C reduced the protective effects of
berberine on cell viability, autophagy, apoptosis, oxidative
stress, angiogenesis, inflammation, and GFAP activation,
implicating AMPK activation in the mechanism of action of
berberine (at time points as defined in Figs. 8B–G). Quantita-
tive analysis of the effects of berberine and berberine
combined with Compound C on HOG-LDL–induced effects
are shown in tabular form (Fig. 8H). The data shown are fold-
changes in expression of the various parameters compared
with HOG-LDL alone: in every case, a potentially beneficial
effect of berberine is inhibited by Compound C.
4-HNE Replicates Most Effects of HOG-LDL on
Mu¨ller Cells
4-HNE is a major fatty acid oxidation product, and has
previously been shown to replicate some effects of HOG-LDL
on Mu¨ller cells.9 In this study, to explore further the use of 4-
HNE as a surrogate for HOG-LDL, we repeated the experiments
described above using 4-HNE in place of HOG-LDL. Using
conditions defined previously,9 Mu¨ller cells were treated with
FIGURE 5. Berberine attenuated HOG-LDL–induced Mu¨ller cell angiogenesis and inflammation. Mu¨ller cells were exposed to HOG-LDL for 24 hours
with/without 1 hour pretreatment with berberine (5 lM). (A–C) Angiogenesis related proteins VEGF and PEDF and VEGF:PEDF ratio; (D)
proinflammation cytokines iNOS and ICAM-1, detected by Western blot and quantified by densitometry (mean 6 SD; n¼3). (E) mRNA levels for IL-
6, IL-8, and TNF-a, measured by real-time PCR and expressed as fold change versus control (mean 6 SD; n ¼ 3).
FIGURE 6. Berberine blunted HOG-LDL–induced Mu¨ller cell activation.
Mu¨ller cells were exposed to HOG-LDL for 24 hours with/without
berberine (5 lM) pretreatment for 1 hour. Mu¨ller cell activation marker,
GFAP, was detected by Western blot and quantified by densitometry
(mean 6 SD; n¼ 3).
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4-HNE at 40 lM for 6 hours. As shown in Supplementary Figure
S3A, 4-HNE decreased cell viability by 50% versus no treatment
control. Berberine attenuated cell death dose-dependently
from 0 to 5 lM, but had no additional effect up to 20 lM. As
it did with HOG-LDL, berberine ameliorated 4-HNE–induced
autophagy, apoptosis, oxidative stress, angiogenesis, GFAP
activation, and inflammatory responses (Supplemental Figs.
3B–G). Taken together, these data support the use of 4-HNE as
a surrogate for HOG-LDL in studies of Mu¨ller cell function.
DISCUSSION
Previously, we demonstrated toxicity of HOG-LDL toward
Mu¨ller cells, and showed that it causes oxidative and ER
stresses, leading to apoptosis.9 We now confirm and extend
these findings, showing that HOG-LDL also activates GFAP, has
proangiogenic and proinflammatory effects in Mu¨ller cells, and
autophagic as well as apoptotic cell death is implicated.
Further, we demonstrate that the harmful effects of HOG-LDL
on Mu¨ller cells can be mitigated by berberine, through a
mechanism partially dependent on AMPK activation (Fig. 9).
We conclude that berberine merits further study as a potential
agent to prevent or treat DR.
Currently, therapies for DR (e.g., laser treatment, intraocular
angiogenic inhibitors) are only applicable to advanced disease;
specific early treatments are lacking. Emerging evidence from
cell culture, animal studies, and clinical trials suggests
beneficial effects of berberine on type 2 diabetes and its
complications.18 In this study, we hypothesized that berberine
protects Mu¨ller cells against modified LDL-induced cytotoxic-
ity. Our findings support the hypothesis but raise new
questions that are not yet answered: does the protection apply
to other retinal cells species exposed to modified LDL; is this a
general effect on cell-modified lipoprotein interaction with
possible benefits beyond DR; and will the in vitro findings
translate to clinical benefit? These questions await answers.
Favorable effects of berberine on various retinal cells have
been demonstrated previously, in vitro, in vivo, and ex vivo. In
human retinal pigment epithelial cells, berberine inhibited IL-
1b–induced BRB breakdown, improving transepithelial electric
resistance and reducing permeability,24 and reduced TNF-a–
induced proinflammatory cytokine production by downregu-
lating the ERK pathway.25 In STZ- and high fat diet-induced
diabetic rats, berberine improved retinal thickness.26 Another
recent in vivo study showed that in mice, by reducing oxidative
stress, berberine can protect against light-induced photorecep-
tor degeneration.27 In an ex vivo study, it inhibited toxicity of
leukocytes derived from diabetic patients toward retinal
endothelial cells.28 However, our study is the first to address
the effect of berberine on toxicity of modified LDL toward
retinal cells. We have accumulated much evidence that
modified LDL is implicated in the progression of DR.4–9 We
now provide in vitro evidence that berberine can protect
Mu¨ller cells against modified LDL-induced cell death and
dysfunction, and we report new detail of its action, and of
the pathophysiologic effects of modified LDL. We show that
berberine acts in part through AMPK pathway activation,
mitigating oxidative stress, autophagic and apoptotic cell
death, Mu¨ller cell activation, angiogenesis, and inflammation.
Interest in berberine has increased dramatically in the past
decade.18 It has been shown to decrease blood glucose,
enhance insulin sensitivity and improve cholesterol levels in
type 2 diabetic rodent models.14,32 It has also shown protective
effects against diabetic complications, including nephropathy,
neuropathy, and cardiomyopathy.23,34–37 In diabetic nephrop-
athy, berberine treatment was shown to improve kidney
function in mice via AMPK activation.35 In a study of diabetic
hypercholesterolemic rats, positive effects of berberine on
cardiac dysfunction were shown, and activation of the
peroxisome proliferator-activated receptor (PPAR)-a and
PPAR-c pathways were implicated.36
In the present study, we showed that berberine protected
Mu¨ller cells against HOG-LDL–induced death. We employed
berberine concentrations ranging from 1.25 to 20 lM, with
most experiments being conducted at 5 lM. We saw no
evidence of any toxic effect of the agent. However, in studies
by others using higher concentrations, toxic effects in cell
culture have been observed38,39: berberine showed toxicity
toward HepG2 cells at 100 lM and toward MHCC97-L cells at
250 lM.38 In another study with primary pancreatic islet cells
from Institute for Cancer Research (ICR; Philadelphia, PA)
mice, berberine protected cells against STZ-induced death at
10 lM, but at greater than 30 lM, it induced cell death39;
similar findings were with human RPE-19 cells, where
berberine became toxic at 50 lM.25 Although berberine has
been used medicinally for three millennia, rigorous studies are
needed to define dosage and safety before any possible long-
term use.
FIGURE 7. Berberine activated the AMPK pathway in a time- and dose-dependent manner. (A) Mu¨ller cells were treated with berberine at various
concentrations for 6 hours. (B) Cells were treated with 5 lM berberine for times indicated. (C) Cells were pretreated with berberine (5 lM, 1 hour)
before being exposed to N- or HOG-LDL (200 mg/L) for 6 hours: untreated cells served as controls, and p-AMPK and t-AMPK were detected by
Western blot. p-AMPK was quantified by densitometry. For all experiments, data shown as mean 6 SD; n ¼ 3.
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As in previous studies, our data suggest multiple actions of
berberine. Previously, we have demonstrated that HOG-LDL
induced apoptosis through oxidative stress in retinal pericytes,
RPE, and Mu¨ller cells.5,6,9 The present study confirms the
finding in Mu¨ller cells, and we now show that berberine can
inhibit ROS production. Others have shown that berberine can
significantly reduce cellular ROS and thereby protect cells
against oxidative stress,40,41 so we measured expression of
relevant proteins. Nox4 is a key enzyme for ROS generation;
Nrf2 is a major component of the ROS signalling pathway
regulating expression of antioxidant proteins; and Gpx-1 plays
an important protective role via ROS detoxification. HOG-LDL
increased Nox4 and reduced Nrf2 and Gpx-1. These changes
were blunted by berberine, which therefore may act both by
reducing ROS generation and increasing ROS removal.
Reactive gliosis is a general response to inflammation and
neuron injury, and in Mu¨ller cells is reflected by increased
GFAP expression. We have demonstrated for the first time that
this activation was inhibited by berberine in Mu¨ller cells
FIGURE 8. Adenosine monophosphate–activated protein kinase activation was implicated in the protective role of berberine on Mu¨ller cells. Mu¨ller
cells were treated with HOG-LDL for 6, 12, or 24 hours with/without berberine (5 lM) or berberineþCompound C (5 lM) pretreatment for 1 hour.
Untreated cells served as control, and DMSO as ‘vehicle control’. (A) Western blots for p-AMPK and t-AMPK, 6 hours 6 pretreatment with
Compound C, 1 hour. (B) Viability expressed as percentage versus control, 24 hours (mean 6 SD; n¼ 3). (C) Cellular ROS levels, 6 hours (mean 6
SD; n¼ 3). (D) Western blots for ATG-5, Beclin-1, cleaved PARP, and cleaved caspase-3, 24 hours. (E) Western blot for VEGF and PEDF (24 hours);
Nox4 and Nrf2, 12 hours. (F) Western blot for iNOS and ICAM-1, 24 hours; GFAP, 24 hours. (G) mRNA levels for IL-6, IL-8, and TNF-a, 24 hours
(mean 6 SD; n ¼ 3). (H) Tabular presentation to show effects (Western blots) of berberine pretreatment (5 lM, 1 hour) or ’berberine plus
Compound C’ pretreatment (each 5 lM, 1 hour) prior to exposure to HOG-LDL (200 mg/L, 12 or 24 hours). In each case, data show fold changes
normalized to the response to ‘‘no treatment’’ control. *P < 0.05, **P < 0.01 versus HOGþPBS, #P < 0.05 versus HOGþBBR treatment (mean 6 SD;
n¼ 3).
FIGURE 9. Hypothesis to explain beneficial effects of berberine on
HOG-LDL–induced Mu¨ller cell dysfunction.
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exposed to HOG-LDL. Neuroprotective effects of berberine
have been shown in other studies.42,43 In gerbils, berberine
ameliorated ischemia–induced activation of microglia in the
hippocampus, evidenced by decreased GFAP expression,42 and
in STZ-induced diabetic rats, berberine attenuated upregu-
lation of cerebral GFAP.43 Interestingly, the latter study showed
that berberine also reduced oxidative stress, consistent with
our findings. The positive effects of berberine on GFAP
regulation may be mediated by its antioxidant effects, but the
mechanism(s) still needs further elucidation.
A precise balance between pro- and anti-angiogenic
proteins, represented by VEGF and PEDF respectively, is
essential for retinal function. This balance is disrupted in
diabetes, and we have hypothesized that exposure of retinal
tissues to modified LDL may be implicated. We now
demonstrate for the first time that in Mu¨ller cells, HOG-LDL
triggers a proangiogenic response, and that this is inhibited by
berberine. The antiangiogenic activity of berberine has
previously been demonstrated in melanoma and lung cancer
cells, where it dramatically decreased VEGF protein and mRNA
expression.44,45
Vascular endothelial growth factor may also promote
inflammation, and increased expression of proinflammatory
cytokines (e.g., IL-6, IL-8, and TNF-a) is characteristic of
DR.46,47 Inhibition of Mu¨ller cell–derived VEGF significantly
decreased retinal expression of TNF-a, ICAM-1, and nuclear
factor-kappa B (NF-jB) in diabetic mice.48 We now show that
HOG-LDL increased iNOS and ICAM-1, and transcriptionally
increased the proinflammatory factors IL-6, IL-8, and TNF-a in
Mu¨ller cells, and that all of these responses were inhibited by
berberine. This is consistent with anti-inflammatory effects
seen in other studies of macrophages and cancer cells.49–51
Adenosine monophosphate-activated protein kinase is a key
signalling system that controls cellular energy balance and
metabolism. Its activation is an important defensive response
to stress and inflammation.52 Berberine is known to activate
AMPK; this effect has been implicated in its beneficial effects in
diabetes53–55 and may lie upstream of many of the effects
described above. In a study of type 2 diabetic mice, berberine
downregulated proinflammatory gene expression; inhibition of
AMPK abolished the effect.49 In the retina, a role for AMPK was
suggested in a study using AICAR, a specific AMPK activator,
which significantly reduced retinal leukocyte adhesion and
VEGF expression.56 Consistent with this, AMPK pathway was
activated by berberine in Mu¨ller cells in a time- and dose-
dependent manner, and pharmacologic inhibition of AMPK
with Compound C partially but significantly attenuated the
protective effects of berberine. Thus Compound C weakened
protective effects of berberine against cell death (apoptosis
and autophagy), angiogenesis, and inflammation, suggesting a
role for AMPK as an upstream regulator of HOG-LDL–induced
Mu¨ller cell dysfunction. A similar role for AMPK was shown in
a study of metformin, another AMPK activator that is widely
used oral antihyperglycemic agent. Metformin significantly
mitigated albuminuria in diabetic mice.55 Thus, AMPK activa-
tion may have therapeutic benefits in the treatment and
prevention of diabetic complications, including DR, but with
the clear and important caveat that animal and cell culture
work may not translate to human disease. It must also be noted
that in our study, inhibition AMPK did not completely block
the protective effect of berberine, suggesting that other
pathways (e.g., PPARa, MAPK) may also be implicat-
ed.16,17,26,36,57 Indeed, it is likely that the harmful intraretinal
effects of extravasated, modified lipoproteins involve several,
or many, pathways. Further work is needed to define their
relative importance in different settings, and agents with more
than one effect, or combinations of agents, may be needed to
block them.
In conclusion, we demonstrate in vitro beneficial effects of
berberine on HOG-LDL–induced Mu¨ller cell death (by inhibi-
tion of autophagic or apoptotic pathways) and dysfunction (by
inhibition of cytotoxicity, oxidative stress, angiogenesis,
inflammation, and GFAP activation). The detailed mechanisms
require further exploration, as do the effects of berberine in
other retinal cell species, but AMPK activation appears to
contribute. The safety of berberine for long-term human use in
either oral or topical preparations needs to be fully established,
and human clinical studies are needed to define any real
benefit for patients. If berberine is capable of mitigating
pathologic effects of modified lipoproteins on other cell types,
it could have benefits that extend beyond diabetic retinopathy.
The present findings support the case for further studies: there
is an urgent need for agents that can block the development of
diabetic complications, and for agents that can block or
mitigate the toxic effects of extravasated, modified lipoproteins
on vascular and neuronal tissues.
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